
https://www.science.org/content/blog-post/how-do-chemist-think-they-judge-compounds
# How Do Chemists (Think That They) Judge Compounds? (November 2012)

## 1. SUMMARY
The article discusses a Novartis study published in PLoS One that examined how medicinal chemists evaluate chemical fragments for drug discovery. Researchers asked 19 Novartis chemists to select desirable compounds from 8 batches of 500 fragments each—a realistic scenario in drug discovery where scientists must choose which compounds to purchase, keep in screening collections, or advance as drug candidates.

The study sought to understand: how chemists simplify complex decision-making, whether different chemists use the same criteria, and whether chemists can accurately report their own decision criteria. The authors analyzed selections using computational classification algorithms (semi-naïve Bayesian and Random Forest) to identify what factors chemists actually prioritized versus what they claimed to prioritize.

The key findings were striking: chemists showed low internal consistency (0.52 similarity when re-evaluating compounds), minimal agreement between chemists (average 0.28 similarity), and poor self-awareness about their own decision-making criteria. Results suggested chemists use only 1-2 key filters rather than complex multi-factor analysis, with individual preferences varying widely—one chemist might prioritize polar surface area avoidance while another focused on molecular size. Most disagreements centered on evaluating good compounds; only 1% of compounds received "good" ratings from at least 75% of chemists, while agreement was much higher on rejecting poor compounds.

## 2. HISTORY
Following the 2012 article, the study's findings reflected a broader, ongoing challenge in drug discovery that continued to drive significant changes in pharmaceutical workflows and computational approaches.

The validation of medicinal chemists' inconsistent compound selection directly contributed to pharmaceutical companies increasingly relying on computational methods and machine learning for early-stage compound evaluation. Between 2012-2022, major pharmaceutical companies (including Novartis, Pfizer, GSK, and Roche) substantially expanded their computational chemistry and AI teams, with many implementing automated compound triage systems. This shift represented a concrete response to the demonstrated inconsistency in human expert judgment.

The methodology established in this research (using machine learning to identify human decision patterns versus stated preferences) influenced subsequent studies across drug discovery. The technique became particularly relevant as pharmaceutical companies faced patent expirations and needed to optimize internal discovery efficiency. Several companies that adopted computational compound prioritization reported measurable improvements in discovery timelines, though specific metrics remain proprietary.

However, the core problem persisted: as of 2024, medicinal chemists still struggle with consistent evaluation of early-stage compounds, though they increasingly work alongside computational prediction tools. The tension between expert intuition and algorithmic decision-making became a central theme in drug discovery, with most pharmaceutical companies adopting hybrid approaches that use both human expertise and machine learning predictions.

The study's broader implication—the gap between stated and revealed preferences in expert decision-making—extended beyond drug discovery and influenced methodological approaches in behavioral economics and expert decision analysis studies published after 2012.

## 3. PREDICTIONS
The original article did not contain explicit predictions about the future. It was primarily observational and analytical, focusing on explaining the implications of the research findings rather than forecasting future developments in the field.

## 4. INTEREST
**Score: 3**

This article highlights an important methodological insight about expert decision-making in drug discovery, but it ranks in the 30th-40th percentile of interest. While the findings about chemists' low self-awareness and poor inter-rater agreement remain relevant to understanding pharmaceutical workflows, the article's narrower scope and modest long-term impact on the broader biotechnology landscape limit its broader historical significance compared to breakthrough drug discovery or therapeutic advancement articles.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20121127-how-do-chemist-think-they-judge-compounds.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_